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ABSTRAK
Tujuan: menganalisis luaran dan kesintasan pasien-pasien osteosarkoma yang menjalani limb salvage 
surgery (LSS) dan amputasi di Rumah Sakit Cipto Mangunkusumo, serta faktor-faktor yang mempengaruhi 
luaran fungsional dan prognosis. Metode: ini adalah studi kohort retrospektif pasien osteosarcoma pada RS 
Cipto Mangunkusumo yang menjalani operasi penyelamatan ekstremitas (LSS), amputasi, LSS + amputasi, 
dan menolak operasi dari tahun 1995-2014. Pemilihan jenis tindakan dilakukan berdasarkan usia, stadium, 
lokasi, keterlibatan neurovaskular, tipe Huvos, kebutuhan fungsional, pilihan pasien, dan keadaan umum 
pasien. Luaran fungsional dinilai dengan skor Musculoskeletal Tumor Society (MSTS) dengan nilai maksimal 
30. Hasil: subjek penelitian meliputi 80 laki-laki dan 52 perempuan berusia 4 hingga 61 tahun. Tindakan yang 
dilakukan meliputi limb salvage surgery (LSS) (n=37), amputasi (n=42), LSS + amputasi (n=2), dan menolak 
pembedahan (n=51). Angka kesintasan 5 tahun kumulatif adalah 14.6%. Angka kesintasan 5 tahun masing-
masing kelompok; LSS, amputasi, kombinasi LSS dan amputasi, dan menolak tindakan masing-masing adalah 
34,8%; 15,9%, 0%, dan 0%. Pasien ukuran tumor <8 cm cenderung menjalani LSS dibandingkan amputasi 
(60,7% vs 39,3%, p=0,046). Angka bebas rekurensi lokal 5 tahun untuk LSS dan amputasi masing-masing adalah 
96,2% dan 86,5% (p=0,586). LSS menunjukkan skor fungsional MSTS yang lebih tinggi dibandingkan dengan 
amputasi (25,0% vs 18,5%, p=0,011). Kesimpulan: kesintasan LSS lebih baik daripada amputasi pada pasien 
osteosarkoma yang dirawat di Rumah Sakit Cipto Mangunkusumo. Luaran fungsional skor MSTS pasien LSS 
lebih baik daripada amputasi. 
Kata kunci: osteosarkoma, limb salvage surgery, amputasi.
ABSTRACT
Aim: to analyze the outcome and survival rate of osteosarcoma patients in our hospital as well as the factors 
affecting prognosis and functional outcome. Methods: this is a retrospective cohort study of osteosarcoma patients 
in Cipto Mangunkusumo Hospital underwent limb salvage surgery (LSS), amputation, LSS + amputation, and 
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refused surgery from year 1995 to 2014. The surgical decision was based on patient’s age, staging, location, 
neurovascular involvement, Huvos type, functional demand, patient preference, and general condition. Functional 
outcome was assessed using the Musculoskeletal Tumor Society (MSTS) score with the maximum score of 30. 
Results: subjects consisted of 80 male and 52 female aged 4 to 61 year-old. They underwent limb salvage 
surgery (LSS) (n=37), amputation (n=42), LSS + amputation (n=2), and refused surgery (n=51). Overall 5-year 
cumulative survival rate was 14.6%. The 5-year survival rate for each group; LSS, amputation, combined LSS 
and amputation, and refused surgery was 34.8%; 15.9%; 0%; and 0%, respectively. Patients with tumor size 
<8 cm tend to underwent LSS compared to amputations (60.7% vs 39.3%, p=0.046). Local recurrence-free 
survival for LSS and amputation was 96.2% and 86.5% respectively (p=0.586). MSTS score was higher in LSS 
than amputation group (25.0 vs 18.5, p=0.011). Conclusion: LSS had higher survival rate than amputation in 
osteosarcoma patients who were treated in Cipto Mangunkusumo Hospital. MSTS functional score in the LSS 
group was higher than amputation group.
Keywords: osteosarcoma, limb-salvage surgery, amputation.
INTRODUCTION
Osteosarcoma is a malignant bone tumor 
derived from primitive mesenchyme cells and 
consists of malignant cells that produce bone and 
osteoid matrix.1-3 It is the most common malignant 
bone tumor of non-hematopoietic origin, which 
is frequently found at the metaphyseal long 
bones such as the distal femur, proximal tibia, 
and proximal humerus during the second decade 
of life.1-3
Incidence of osteosarcoma in all population 
is approximately 4-5 per 1,000,000 population.3 
It is higher in adolescents to 8-11 per one 
million population per year at the age of 15-19 
years.4-5 In the United States, osteosarcoma are 
the most common primary malignancy of bone, 
representing approximately 56% of malignant 
bone tumors in children.6-7 Osteosarcoma is 
also the most common primary malignant bone 
tumor in Cipto Mangunkusumo Hospital (CMH) 
Jakarta, Indonesia. Kamal et al.8 reported 16.8 
osteosarcoma new cases per year (total number 
219 patients) who came to CMH from 1995 to 
2008.
Because of the rapid and aggressive nature 
of this tumor, the standard management for 
osteosarcoma is limb amputation.9-10  However, 
over the past 3 decades, since the development 
of effective chemotherapy agents has reduced 
the incidence of metastasis, the prognosis 
for patients with osteosarcoma has changed 
dramatically.11-12 Multiple studies have shown 
the results of limb-salvage operation compared 
to amputation.13-14 Simon et al.15 and Rougraff et 
al.16 have reported that the survival of patients 
with either limb salvage or amputation is no 
different, although there is a higher rate of local 
recurrence in patients with limb salvage. It is 
generally accepted that, if the surgery is carried 
out in an appropriate oncological manner, there 
is no detriment to the survival of patients treated 
with limb salvage in a variety of techniques.17-18
The aim of limb salvage surgery (LSS) is 
to widely resect the local tumor and to preserve 
normal soft tissue as much as possible, thus provide 
a well-functioning, tumor-free, and painless 
limb. Many options of LSS have been developed, 
including resection arthrodesis, resection and 
reconstruction using bone graft (autograft, 
allograft, extracorporeally irradiated autograft 
or endoprosthetic composite), endoprosthesis 
reconstruction, Ilizarov lengthening technique, 
rotation plasty, etc.13-14,18-19
In this study, we analyze the outcome and 
survival rate of osteosarcoma patients as well 
as the factors affecting prognosis in Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia.
METHODS
This is a retrospective cohort study using 
secondary data from musculoskeletal oncology 
registries, medical records, and follow up care 
in outpatient clinic or home visit treated in Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia, 
from 1995 to 2014. All lesions were clinically, 
radiologically, and histologically confirmed as 
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osteosarcoma.
For each patient, we recorded gender, age, 
presenting symptom and its duration, tumour 
size, location, haemoglobin, serum alkaline 
phosphatase (SAP), type of biopsy performed, 
histologic type of osteosarcoma, Huvos grade and 
treatment performed. We evaluated the presence 
of local recurrence, metastasis, musculoskeletal 
tumor society (MSTS) functional outcome score, 
and survival after treatment.
Age was classified in groups of decades. 
Presenting symptoms were mass, pain, mass and 
pain, and bleeding. Duration of symptoms were 
measured in months. Tumor size was divided 
in 2 groups (<8 cm and >8 cm). Type of biopsy 
were divided into fine-needle aspiration biopsy 
(FNAB), core neddle biopsy, open biopsy, or 
combination between those. Types of patient 
management were divided into operative (LSS 
or amputation or both), chemotherapy only, and 
refused treatment. Local recurrence was detected 
by physical, radiologic, and histopathology 
examinations. Metastasis was detected by chest 
X-ray, computed tomography (CT) scan, and/or 
bone scintigraphy. Osteosarcoma patients who 
did not complete the profile data and the follow 
up of their condition were excluded.
Statistical analysis was performed using 
Statistical Program for Social Sciences (SPSS) 
software version 20. Chi-square analysis was 
performed to evaluate the tumor and patients’ 
demographics and its correlation to the presence 
of local recurrence, metastases, complications, 
and mortality rate. Kaplan-Meier curve was used 
to describe the survival in the univariate analysis, 
its correlation with types of surgery, time to event 
analysis where as time to local recurrence were 
analyzed by log rank test. A p-value of 0.05 was 
considered as statistically significant.
This study had been approved by Research 
Ethics Committee, Faculty of Medicine 
Universitas Indonesia, Cipto Mangunkusumo 
Hospital number 247/H2.F1/ETIK/2014.
RESULTS
During January 1995 to June 2014 period, 
there were 132 consecutive osteosarcoma 
patients who were included in the study. Seventy 
six (57.6%) patients were in relatively young age 
group (11 - 20 year-old) with median of 17.5 
year-old (interquartile range 14.0 - 23.0 year-
old). Male and female patients were 80 (60.6%) 
and 52 (39.4%) respectively.  The most common 
complaint was mass (79.5%) with median 
duration of 4.0 months (interquartile range 3.0-
7.8 months), poor general condition (62.1%), 
relatively low hemoglobin level (median 11.6; 
interquartile range 9.7-13.3) and elevated level 
of alkaline phosphatase (56.2%). Patients with 
tumor size smaller than 8 cm tend to undergo 
LSS (60.7%) compared to amputation (60.7% 
vs 39.3%, p=0.046) (Table 1).
Overall local recurrence-free survival 
for osteosarcoma patient was 93.4%. Five 
year local recurrence-free survival for LSS 
and amputation showed 96.2% versus 86.5% 
(p=0.586), respectively (Table 2). MSTS score 
in LSS group was significantly higher than 
amputation group (25.0 versus 18.5, p=0.011). 
However, no statistically significant difference 
was found between two surgical techniques to the 
MSTS score category (Table 3). The mortality 
rate in amputation group was higher compared 
to the LSS group (p = 0.038) (Table 4).
Overall, the proportion of 5-year cumulative 
survival rate was 14.6%, where as the LSS, 
amputation, combined LSS and amputation, 
and refused treatment had 5 year survival rate of 
34.8%; 15.9%; 0%; and 0%, respectively. LSS 
group had the highest survival rate (Figure 1).
Table 1. Characteristics of osteosarcoma patients in Cipto 
Mangunkusumo Hospital
Characteristics N=132
Age, years, median (IQR) 17,5 (14,0–23,0)
Age groups, years, n (%)
 - 0 -10 12 (9.1)
 - 11-20 76 (57.6)
 - 21- 30 22 (16.7)
 - 31- 40 11 (8.3)
 - >40 11 (8.3)
Gender
 - Male 80 (60.6)
 - Female 52 (39.4)
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 - Mass 105 (79.5)
 - Pain 18 (13.6)
 - Mass and pain 7 (5.3)
 - Bleeding 2 (1.5)
Symptom duration, months, 
median (IQR)
4 (3.0-78)
General condition, n (%)
 - Poor 82 (62.1)
 - Moderate 24 (18.2)
 - Good 26 (19.7)
Hemoglobin, mg/dL, median (IQR) 11.6 (9.7-13.3)
Alkaline phosphatase, IU/L, 
median (IQR)
334 (185-666)
 - Normal 57 (43.8%)
 - Elevated (>270) 73 (56.2%)
Tumor size, cm, median (IQR) 12.0 (8.0-20.0)
 - <8 cm, n (%) 41 (31.1)
 - >8 cm, n (%) 91 (68.9)
Tumor location, n (%)
 - Femur distal 52 (42.4)
 - Femur proximal 4 (3.0)
 - Knee/patella 4 (3.0)
 - Tibia distal 5 (3.8)
 - Tibia proximal 42 (31.8)
 - Fibula distal 1 (0.8)
 - Fibula proximal 2 (1.5)
 - Humerus distal 3 (2.3)
 - Humerus proximal 7 (5.3)
 - Radius distal 1 (0.8)
 - Radius proximal 1 (0.8)
 - Forearm 1 (0.8)
 - Clavicle 2 (1.5)
 - Pelvis/ischium/ilium/sacrum 2 (1.5)
 - Rib 3 (2.3)
 - Foot/ankle 2 (1.5)
Table 1. Characteristics of osteosarcoma patients in Cipto 
Mangunkusumo Hospital
Characteristics N=132
Stage (Enneking), n (%)
 - Stage IIB 101 (78.2)
 - Stage III 31 (25.7)
Huvos Type, n (%)
 - Huvos I 9 (33.3)
 - Huvos II 7 (25.9)
 - Huvos III 9 (33.3)
 - Huvos IV 2 (7.4)
 - Responsive 11 (40.7)
 - Unresponsive 16 (59.3)
Histological type, n (%)
 - Conventional 121 (91.7)
 - Giant cell rich 6 (4.5)
 - Small cell 4 (3.0)
 - Periosteal 1 (0.8)
Biopsy type, n (%)
 - FNAB 104 (78.8)
 - Open biopsy 16 (12.1)
 - Core biopsy 12 (9.1)
Type of surgery, n (%)
 - Limb salvage surgery (LSS) 37 (28.0)
 - Amputation 42 (31.8)
 - LSS + amputation 2 (1.5)
 - Refused treatment 51 (38.6)
Table 2. Local recurrence-free survival and average time-to-local recurrence
5-year local recurrence-free  
(95% CI) p value
Average time-to-local recurrence  
(95% CI)
Overall 93.4 (83.6–103.2) 0.586 168.3 (151.5–185.887)
LSS 96.2 (88.4–104.0) 164.3 (154.2–174.4)
Amputation 86.5 (66.9–106.1) 158.6 (123.5–193.7)
DISCUSSION
Conventional osteosarcoma is more common 
in men than women by a ratio of 3 : 2. The tumor 
most commonly affect patients within the 2nd 
decade of life and more than 60% in patients less 
than 25 years old. The incidence of osteosarcoma 
is also increased at the 6th decade of life, so 
the disease has a bimodal distribution.3,20,21 
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MSTS Score, median (IQR) 25.0 (20.0-26.0) 18.5 (11.8–23.3) 0.011
MSTS score percentage, %, 
median (IQR) 83.3 (66.7–86.7) 61.7 (39.2–77.5) 0.011
MSTS score category, n (%)
 - Poor 0 (0.0) 1 (100.0) 0.212
 - Fair 1 (33.3) 2 (66.7)
 - Good 5 (55.6) 4 (44.4)
 - Very good 11 (78.6) 3 (21.4)
 - Poor – Fair 1 (25.0) 3 (75.0) 0.128
 - Good – Excellent 16 (69.6) 7 (30.4)
Table 4. Mortality in relation to treatment, metastasis, and complication
Parameter




 - LSS 20 (54.1) 17 (45.9) 0.038
 - Amputation 32 (76.2) 10 (23.8)
Metastasis, n (%)
 - Yes 55 (98.2) 1 (1.8) 0.001
 - No 47 (61.8) 29 (38.2)
Complication, n (%)
 - Yes 5 (55.6) 4 (44.4) 0.118
 - No 97 (78.9) 26 (21.1)
Osteosarcoma can occur in all bones, with the 
predilection site of metaphyseal region of the 
long bones (91%). Distal femur and proximal 
tibia are the most common locations followed 
by proximal humerus, sometimes found in the 
diaphysis of long bones, but rarely found in the 
flat bones.1,3,4,20
In our study, male and female ratio is 1.54 : 1 
with peak incidence in the second decade of life 
followed by the third decade. Distal femur and 
proximal tibia are the most common locations 
of osteosarcoma. Our result is similar with other 
study reported by Picci et al.22 during 21 years 
of follow-up at one institution. The author also 
reported that osteosarcoma is more common 
in male patients, mostly in second and third 
decade of life with conventional osteosarcoma 
as the most common type and the most common 
location is in distal femur and proximal tibia. Tan 
et al.23 also reported similar results.
Osteosarcoma patients usually come to the 
hospital because of pain that is initially mild 
and intermittent, but progressively becomes 
more intense and persistent. Another common 
complaint is a lump in the extremities that swells 
rapidly and painful. Tumor at the area near the 
joints often disturbs joint function. Pathological 
fractures can occur in 5-10% of osteosarcoma 
patients.2,3 The other common symptoms are 
weight loss, fever, and malaise.1,3,4
Laboratory tests are needed to assess patient’s 
general condition but cannot be the basis of 
diagnosis.4 Increase in SAP (serum alkaline 
phosphatase) usually occurs in osteosarcoma. 
SAP level evaluation to show osteoblast activity 
are done regularly. The level of bone-specific 
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Figure 1. (a) Overall survival curve for osteosarcoma patients. Survival curve was based on Kaplan-Meier method. (b) 
Comparison of survival curves according to the type of management of LSS, amputation, combined LSS and amputation, 
chemotherapy alone, and refused treatment.
B
alkaline phosphatase (BSAP), although not 
specific for osteosarcoma should be used as a 
reference for a follow-up marker of metastasis 
and recurrence.3,21 In our study, SAP values 
were divided into normal (43.2%) and increased 
(55.3%).
In the management of osteosarcoma, biopsy 
plays a very important role for diagnosis. A 
biopsy can be done with FNAB, core biopsy, 
or open biopsy. FNAB is a technique which 
is simple, relatively safe and cheaper than the 
open biopsy with 70-90% diagnostic accuracy in 
determining the malignant primary bone lesions. 
FNAB can also be done in the outpatient clinic, 
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thus saving time and cost of hospitalization. 
Neoadjuvant chemotherapy can also be given 
after FNAB. Another advantage is it only cause 
little interference or damage to soft tissue 
and bone with minimal risk of pathologic 
fractures.27-30 In our hospital, open biopsy in bone 
tumor is only performed if the result of FNAB 
or core biopsy was inconclusive or inconsistent 
with the clinical and radiological findings.
From 132 patients in this study, only 81 
patients underwent surgery with 28.0%, 31.8%, 
and 1.5% patients underwent LSS, amputation, 
and both procedures, respectively. The remainder 
of patients who refused surgery were further 
classified into receiving chemotherapy only 
(23.5%) and refused all treatment (15.2%). 
Patients who only received chemotherapy came 
to the our hospital with enormous size of tumour 
that were indicated for amputation but refused it 
or due to advanced condition. They who refused 
any therapy possibly due to various factors 
such as socio-economic, health insurance, and 
beliefs. Many still believe that chemotherapy 
may worsen patient’s condition and many are 
still afraid to undergo surgery. In general, these 
two groups (chemotherapy alone and refused 
any therapy) mostly came from patients that seek 
treatment before 2005. However after that era, our 
government provided national health insurance 
system for all Indonesian resients and made them 
easier to gain health services in any level hospital. 
Therefore, many patients came to the health care 
center early.
In our study, tumor size and staging of cancer 
are the important factors which determine type 
of surgery. Patients with tumor size smaller than 
8 cm tended to undergo LSS. Osteosarcoma 
patients with stage IIB who underwent the LSS 
were less than those underwent amputation 
(52.6%). However, those with stage III tended to 
undergo amputation (58.8%) compared to LSS. 
Several important factors to be considered for 
amputation are: large size tumor, neurovascular 
involvement, the presence of ulcer, hemorrhage 
from the tumor, and pathologic fracture. Although 
in several cases of pathologic fracture, LSS 
could be performed as long as the neoadjuvant 
chemotherapy gave good response.
High SAP values is one of the factors that 
determine prognosis. Other prognostic factors 
include age ≤ 14 years, tumor volume > 200 mL, 
inadequate surgery, chemotherapy with a regimen 
of two drugs and poor histologic response to 
chemotherapy.21,24-26 In this study, LSS group 
had higher survival rate than amputation group, 
with median survival time of 23.9 months. We 
believe that these results may be due to more 
complete chemotherapy in the group LSS. Other 
factors that influenced our patients’ survival are 
improvement of reconstruction technique of LSS 
and biopsy type (FNAB). They also affect the 
increase in survival of patients.31
We found a 5-year survival rate of 
osteosarcoma patients 14.6%. However, 5-year 
survival rate in patients who underwent LSS 
was 34.8%. In other words, the LSS group had 
higher survival rate than amputation group. 
LSS group also had better result compared to 
chemotherapy alone or no treatment groups. It 
might be due to the patients who were performed 
LSS received more complete chemotherapy 
compared to amputation group or more complete 
management (chemotherapy and surgery) than 
last two groups. This result is in contrast to Tan 
et al.23 who reported a 5-year survival rate of 
61.8% and Foster et al.32 in Canada who obtained 
5-year survival rate of 62%. Great difference in 
survival rate may be influenced by several factors 
such as the poor general condition of patients, 
large tumor size, chemotherapy completeness, 
unresponsive to chemotherapy (Huvos grading), 
and complications.
Patients who underwent LSS have a local 
recurrence rate of 3.8%, lower than patients 
who underwent amputation which is 13.5%. 
This result is in contrast to a study by DiCaprio 
et al.33 who reported the incidence of local 
recurrence were higher in LSS group compared 
to amputation. Picci et al.34 reported that local 
recurrence in LSS and amputation were 7% and 
2.4%, respectively.
Some patients showed poor response to 
chemotherapy as showed with Huvos histologic 
grading (55.6%), while the rest showed good 
response to chemotherapy (44.4%). These results 
differ from previous study that was reported by 
Bacci et al.13 that showed histologic response 
to chemotherapy was good in 63% of patients.
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Histological response to chemotherapy is worse 
in our hospital may be due to resistance of 
chemotherapy regiments, different regiment type 
(in pediatric type), or larger tumor size. However, 
it is still needed for further evaluation.
A number of patients died (80%) with 
3.3% and 6.7% experienced local recurrence 
or complication, respectively. The percentage 
of patients in stage III with metastases who had 
good and excellent functional status (66.7%) 
were lower than patients in stage IIB (85.7%). 
Unfortuntely, most of patients died and only 
21.6% survived. On the contrary, only 35.1% 
patients experienced metastasis compared to 
those who did not (64.9%). The mortality rate 
in the amputation group was significantly higher 
than the LSS group. High mortality rate was 
found in patients with metastases compared to 
those who did not. Thus, it is concluded that 
metastases greatly affects survival. This result 
is consistent with other studies which mentioned 
rate of local recurrence and metastasis are 
important prognostic factors.35
Metastasis to the lung is the most common. 
However, metastasis also occur to other bones 
(spine, acetabulum, cranium), lymph nodes, 
and heart. In our study, patients undergoing 
amputation were more likely to experience 
metastasis compared to LSS. This could be due 
to more patients in the amputation group did not 
receive complete chemotherapy. Only 16.6% of 
patients received complete chemotherapy. Ward 
et al.18 reported tumor necrosis percentage of 
below 90% and inadequate chemotherapy were 
important risk factors associated with metastasis 
and death.
The functional outcome based on MSTS 
system score in LSS group was significantly 
higher compared to amputation group (83.3% 
versus 61.7%). Patients who did not experience 
local recurrence were likely to have good and 
excellent functional outcome, whereas those with 
local recurrence had worse score. These results 
are supported by previous studies that mentioned 
functional outcomes in patients with LSS 
procedure were better than amputation (without 
affecting the survival rate).16,36-38 Aksnes et al.39 
reported that amputation was one of the factors 
associated with low physical function. Patients 
without metastasis and complications tend to 
have good and excellent functional scores.
CONCLUSION
In our study, tumor size and staging of 
osteosarcoma were the important factors which 
determine type of surgery. Combination of 
surgery and chemotherapy gave better survival 
than chemotherapy only. We confirmed that 
LSS had higher survival rate than amputation 
in patients received complete chemotherapy in 
Cipto Mangunkusumo Hospital. Survival rate 
was influenced by the type of surgery, general 
condition, tumor size, chemotherapy completeness 
and responsiveness (Huvos grading). MSTS 
functional score in the LSS group was better than 
those in amputation group. Patients who did not 
have metastasis and complication tended to have 
good and excellent functional scores.
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